In March 2019, the Medical Research Agency signed a memorandum on cooperation in the scope of clinical research development with a leading oncology centre - the MD Anderson Cancer Center. The letter of intent assumes establishing joint research and scientific programmes as well as undertaking joint clinical trials, with special attention paid to non-commercial trials. The University of Texas MD Anderson Cancer Center is one of the most appreciated world centres for fighting cancers.
The Memorandum was signed by Professor Łukasz Szumowski, the Minister of Health, Radosław Sierpiński, MD, PhD, acting as the President of the Medical Research Agency and prof. George Wilding, Vice-President of MD Anderson. Cooperation with MD Anderson provides us with huge opportunity to develop our clinical studies in the area of oncology which, in turn, will result in improving the quality of oncological care in Poland. The signed agreement will also contribute to both development of joint research programmes, as well as to participation of Polish researchers in key international cancer studies.
The Letter of Intent with pharmaceutical companies
The agreement concluded between the Medical Research Agency and pharmaceutical companies concerns supporting enterprises in conducting and developing innovative activities in the field of medical sciences, health sciences and interdisciplinary projects in healthcare, with particular emphasis on artificial intelligence, and also includes joint actions aimed at developing new technologies and scientific research in health care.
The cooperation shall include joint organisation of workshops, conferences, seminars and trainings, as well as creation of initiatives of experts in the form of think-tanks.
Pharmaceutical companies, which signed the letter: Amgen, AstraZeneca, KCR, Roche Poland, Bristol-Myers Squibb, Takeda Pharma, Eli Lilly Poland, Janssen Poland, Pfizer Poland, Mylan Healthcare, MSD Poland, Medtronic Poland, Novartis Poland.